|
|
|
| The Effect of Dapagliflozin on Type 2 Diabetes Mellitus with Cardiac Insufficiency and Its Influence on Cardiac Function Platelet Lymphocyte Ratio and Plasma Hcy Level |
| WANG Zhuoqun, SHEN Jinfu, NIU Min, et al |
| Fuyang People's Hospital, Anhui Fuyang 236000, China |
|
|
|
|
Abstract Objective: To explore the effect of Dapagliflozin on heart function, platelet lymphocyte ratio (PLR) and plasma homocysteine (hcy) in patients with type 2 diabetes mellitus. Methods: 171 patients with type 2 diabetes mellitus complicated with cardiac insufficiency in our hospital from January 2019 to January 2020 were randomly divided into comparison group (n=85) and observation group (n=86). Clinical efficacy, blood glucose level [glycosylated hemoglobin (HbA1c), fasting blood glucose (FPG) and 2h postprandial blood glucose (2hPG)], cardiac function [left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD) and 6 min walking test (6MWT)], PLR, plasma hcy level and adverse reactions were compared between the two groups. Results: The total effective rate of the observation group was 94.19%, which was significantly higher than that of the control group (84.71%) (P<0.05); after treatment, compared with the control group, the observation group had significantly lower levels of HbA1c, FPG and 2hPG (P<0.05), LVEF, 6MWT levels were significantly higher (P<0.05), LVEDD, PLR, and plasma hcy levels were significantly lower (P<0.05); the incidence of adverse reactions in the observation group was 10.47%, slightly higher than 5.88% in the control group. (P>0.05). Conclusion: Dapagliflozin for patients with type 2 diabetes complicated with cardiac insufficiency has a good clinical effect, which can obviously improve the blood glucose level and cardiac function of patients, regulate PLR and plasma hcy levels, and has good safety.
|
|
|
|
|
|
[1] 李玉,段敬柱.心理应激对冠心病合并2型糖尿病患者PCI术后糖代谢、胰岛素抵抗及炎症介质水平的影响[J].中国健康心理学杂志,2019,27(1):89~92.
[2] Diabetic Cardiomyopathy:Definition,diagnosis,and therapeutic implications[J].Heart fail clin,2019,15(3):341~347.
[3] 胡姗姗,肖莉,胡菁,等.阿托伐他汀联合苯那普利治疗冠心病合并2型糖尿病心功能不全者56例疗效观察[J].中国临床医生杂志,2018,46(11):1296~1299.
[4] Dawwas G K,Smith S M,Haesuk P.Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes[J].Diabetes Obes Metab,2019,9(1):28~36.
[5] 贾伟平,陆菊明.中国2型糖尿病防治指南(2017年版)[J].中华医学会糖尿病学分会,2018,10(1):2,67.
[6] 林少华,陈美卿.盐酸曲美他嗪治疗2型糖尿病合并慢性心功能不全患者的临床效果分析[J].中国当代医药,2018,25(23):158~161.
[7] 余凤,夏漫,刘丹,等.老年2型糖尿病患者HbA1c与CYFRA21-1、CA199水平的相关性分析[J].糖尿病新世界,2021,24(3):7~9.
[8] 郭丽婷,葛焕琦,高志红.达格列净对使用胰岛素联合利拉鲁肽或沙格列汀治疗不理想的2型糖尿病患者影响的研究[J].中国糖尿病杂志,2019,27(5):343~346.
[9] 游月婷,汪汉,徐俊波.达格列净在心力衰竭治疗中的研究进展[J].心血管病学进展,2020,41(8):830~833.
[10] 史晓荻,魏志杰.SGLT-2抑制剂联合常规降糖治疗对2型糖尿病患者血管内皮功能的影响[J].安徽医学,2020,41(1):42~46.
[11] 王彦春,张俊峰,周星璇.动态监测外周血NLR和PLR预测STEMI合并2型糖尿病患者PCI术后短期预后的价值[J].广东医学,2019,40(4):142~146.
[12] 杨震,董健,张军涛,等.达格列净在2型糖尿病合并心功能不全患者中应用的临床评价分析[J].重庆医学,2019,48(16):2861~2863. |
|
|
|
2021, Vol. 27 
